The Role of Adipokines In Atrial Fibrillation

NCT03592732 | Unknown

• 1 other identifier: 308/29-3-2018
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The principal aim of the present study is to analyze adiponectin, omentin-1, apelin and visfatin plasma levels in patients with and without AF in an effort to identify their potential role in the development of AF.

Conditions

Atrial Fibrillation; Adiposity; Adiponectin; Visceral Obesity; Hormone Disturbance

Outcome Measures

Primary Outcomes (1)

• adiponectin, omentin-1, apelin and visfatin plasma levels

  adiponectin, omentin-1, apelin and visfatin plasma levels calculation by the Eliza method

  blood sample collection analysis (day zero

Study Arms (2)

A

Patients with atrial fibrillation

Other: Blood sample

B

Patients without atrial fibrillation

Other: Blood sample

Interventions

Blood sample OTHER

Blood sample

A; B

Eligibility Criteria

• Age: Up to 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All participants will undergo either electrocardiogram or 24-hour Holter monitoring. AF patients will be divided into the following three groups: paroxysmal AF, persistent AF and permanent AF.Blood samples will be collected after 12-hour overnight fasting. Plasma adiponectin, omentin-1, apelin and visfatin levels will be measured by the Elisa method. Natriuretic peptide, C-reactive protein (CRP) and parameters concerning lipid profile (total cholesterol, triglycerides, low-density cholesterol, high-density cholesterol), glycemic profile (plasma glucose, hemoglobin A1c) and renal function (urea, creatinine) will be measured by standardized enzymatic methods as well. Transthoracic echocardiography will be performed in every patient.

You may qualify if:

• healthy subjects without atrial fibrillation and subjects with paroxysmal, persistent or permanent atrial fibrillation

You may not qualify if:

• Patients with coronary artery disease, acute coronary syndrome, heart failure (EF\<50%), cardiomyopathy, cancer, significant valvular disease, rheumatic heart disease, chronic kidney disease (eGRF\<30) or stroke will be excluded.

Sponsors & Collaborators

• University of Athens: lead

Study Sites (1)

LAIKO General Hospital, Athens, Greece

Athens, 11522, Greece

RECRUITING

MeSH Terms

Conditions

Atrial Fibrillation; Obesity; Obesity, Abdominal; Endocrine System Diseases

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• Elias Sanidas, MD, PhD

  Dept. of Cardiology, ESH Excellence Center, LAIKO General Hospital, Athens, Greece

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Maria Velliou, MD

CONTACT

+306977445920; maravelliou84@yahoo.gr

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 28, 2018
• First Posted: July 19, 2018
• Study Start: March 29, 2018
• Primary Completion: January 29, 2021
• Study Completion: January 29, 2021
• Last Updated: February 1, 2021

Record last verified: 2021-01

Locations

GR (1)